These along with no increase in ubiquitin mediated proteosomal degradation by pharmaceutical CDK9 inhibitors, suggest that CDK9 transcriptionally regulates MCL-1 in esophageal adenocarcinoma. The gene discussed is MCL1; the disease is esophageal adenocarcinoma.